Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:BFRA

Biofrontera (BFRA) Stock Price, News & Analysis

Biofrontera logo

About Biofrontera Stock (NASDAQ:BFRA)

Advanced Chart

Key Stats

Today's Range
$2.51
$2.78
50-Day Range
$2.50
$3.60
52-Week Range
$2.09
$7.54
Volume
7,263 shs
Average Volume
27,512 shs
Market Capitalization
$73.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Receive BFRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

BFRA Stock News Headlines

Market down? Do this now.
During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.
PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET -2-
Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC
See More Headlines

BFRA Stock Analysis - Frequently Asked Questions

Biofrontera AG (NASDAQ:BFRA) posted its quarterly earnings data on Wednesday, November, 24th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.03. The business had revenue of $6.34 million for the quarter. Biofrontera had a negative trailing twelve-month return on equity of 93.31% and a negative net margin of 59.44%.

Biofrontera (BFRA) raised $18 million in an initial public offering (IPO) on Wednesday, February 14th 2018. The company issued 1,500,000 shares at a price of $11.00-$13.00 per share. Benchmark acted as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biofrontera investors own include AMC Entertainment (AMC), AC Immune (ACIU), Adaptimmune Therapeutics (ADAP), ADMA Biologics (ADMA), Ashford Hospitality Trust (AHT), Akebia Therapeutics (AKBA) and Assembly Biosciences (ASMB).

Company Calendar

Last Earnings
11/24/2021
Today
2/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BFRA
Employees
138
Year Founded
N/A

Profitability

Net Income
$-14,880,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$36.19 million
Book Value
$0.35 per share

Miscellaneous

Free Float
N/A
Market Cap
$73.73 million
Optionable
Not Optionable
Beta
1.02
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:BFRA) was last updated on 2/24/2025 by MarketBeat.com Staff
From Our Partners